cAMP Second Messenger Pathway
A single molecule of adrenaline binding a liver cell can liberate millions of glucose units within seconds. How does one hormone, docking briefly on the cell surface, unleash a metabolic flood inside a cell it never enters? The answer is a small, diffusible chemical relay called cyclic AMP (cAMP). It is synthesized just inside the plasma membrane. It then spreads through the cytoplasm to activate an enzyme. This enzyme reprograms cell behavior by phosphorylating dozens of targets. This pathway matters because it is the prototype for the entire logic of hormone and neurotransmitter action in animals. A hydrophilic signal that cannot cross the membrane is translated into an intracellular chemical signal. This signal is then amplified and distributed to multiple effectors. The same core module — receptor, G protein, adenylyl cyclase, cAMP, protein kinase A — underlies glucagon and adrenaline action on liver and muscle metabolism. It also underlies the sense of smell, cardiac rate control, and even long-term memory formation in the hippocampus. Its dysregulation causes disease directly. Cholera toxin permanently switches the pathway on, causing catastrophic fluid loss. Mutations in this machinery are also implicated in certain endocrine tumors. The big picture is that cells solve a signal-transduction problem. They must get information from outside to inside, and amplify it. They do this using a strategy of enzymatic cascades rather than a single lock-and-key event. cAMP is the second messenger. The receptor and its bound hormone are the "first messenger." But it is cAMP, made and destroyed inside the cell, that actually carries the instruction to the cell's interior machinery. Understanding this pathway requires connecting three levels of description. These are the biochemistry of a single enzyme reaction, the geometry of a membrane-anchored signaling complex, and the systems-level behavior of amplification and reversibility. This article works through the molecular mechanism from receptor to phosphorylated substrate. It covers the classic experiments — largely from Earl Sutherland's laboratory — that discovered cAMP. These experiments established the second-messenger concept. The article also includes two fully worked quantitative examples, common conceptual traps, and the biomedical stakes of this pathway today.
- Hormone binding a G-protein-coupled receptor (GPCR) activates a stimulatory G protein (Gs), whose Gα-GTP subunit turns on adenylyl cyclase.
- Adenylyl cyclase converts ATP into cyclic AMP (cAMP), a small diffusible second messenger that carries the signal into the cytoplasm.
- cAMP binds the regulatory subunits of protein kinase A (PKA), releasing active catalytic subunits that phosphorylate serine/threonine residues on target proteins.
- Phosphorylation targets include metabolic enzymes (e.g., glycogen phosphorylase kinase), ion channels, and the transcription factor CREB, giving both fast and slow (transcriptional) responses.
- Sutherland's experiments with liver extracts and glucagon proved a heat-stable intermediate — cAMP — links hormone binding to enzyme activation, defining the second-messenger concept.
- Phosphodiesterase degrades cAMP, terminating the signal; caffeine and related drugs act by inhibiting this enzyme, prolonging cAMP action.
A hormone that never enters the cell still controls it, because adenylyl cyclase converts that surface signal into a diffusible intracellular messenger, cAMP, which amplifies and distributes the instruction by activating protein kinase A throughout the cytoplasm.
The core idea
The cAMP pathway is the founding example of second messenger signaling: a small, freely diffusible intracellular molecule that relays and amplifies information from a cell-surface receptor to intracellular effectors. It operates downstream of Heterotrimeric G Proteins as Molecular Switches, extending the GPCR signaling logic one step further into the cytoplasm. The core chain of events is: hormone (first messenger) → GPCR → heterotrimeric G protein → adenylyl cyclase (effector enzyme) → cyclic AMP (second messenger) → protein kinase A (PKA) → phosphorylation of target proteins → altered cell behavior. Two properties define why cAMP works so well as a messenger. First, it is made from a molecule already abundant in every cell — ATP — so no new synthetic machinery for a substrate is needed; only the enzyme controlling its production must be regulated. Second, cAMP is rapidly and continuously destroyed by phosphodiesterases, so its concentration reflects the current rate of synthesis versus degradation, not an accumulating history. This turnover gives the system fast on/off kinetics, essential for signals that must track rapidly changing external conditions (e.g., a sprint requiring immediate glycogen breakdown). The pathway also exemplifies amplification: each activated receptor can activate many G proteins, each activated adenylyl cyclase can make many cAMP molecules, and each PKA holoenzyme releases catalytic subunits that phosphorylate many substrate molecules. A single hormone-receptor binding event is converted, through this multi-tier cascade, into thousands to millions of downstream phosphorylation events — the biochemical basis of why trace hormone concentrations (picomolar to nanomolar) can produce large physiological effects.
Mechanism
Step 1 — Receptor activation. A hormone such as glucagon, adrenaline (epinephrine), or ACTH binds the extracellular face of a Gs-protein-coupled receptor, a seven-transmembrane-helix protein. Ligand binding causes a conformational shift in the receptor's transmembrane helices, exposing an intracellular surface that acts as a guanine-nucleotide exchange factor (GEF) for the associated heterotrimeric G protein.
Step 2 — G protein cycling. The receptor catalyzes GDP release from the Gα subunit of the stimulatory G protein, Gs, and GTP (abundant in cytoplasm, ~10-fold more concentrated than GDP) binds in its place. GTP-loaded Gαs dissociates from Gβγ and from the receptor, and diffuses laterally in the membrane to find adenylyl cyclase.
Step 3 — Adenylyl cyclase activation. Gαs-GTP binds and allosterically activates adenylyl cyclase (AC), a multi-pass transmembrane enzyme with its catalytic core facing the cytoplasm. Activated AC catalyzes: ATP → cyclic AMP (3′,5′-cyclic adenosine monophosphate) + pyrophosphate (PPi) The reaction cyclizes the phosphate group onto the 3′ hydroxyl of ribose, forming a strained, energetically favorable ring; subsequent hydrolysis of PPi by pyrophosphatase makes the overall reaction essentially irreversible in the cell, driving cAMP accumulation.
Step 4 — cAMP diffusion and PKA activation. cAMP diffuses freely through the cytosol (it is small and uncharged relative to nucleotide triphosphates) and binds the regulatory (R) subunits of protein kinase A (PKA). The inactive PKA holoenzyme is an R2C2 tetramer — two regulatory subunits, each bound to and inhibiting a catalytic (C) subunit. Each R subunit has two cAMP-binding (cyclic nucleotide-binding, CNB) domains; cooperative binding of four cAMP molecules (two per R subunit) causes a conformational change that releases the two catalytic subunits as free, active kinases.
Step 5 — Substrate phosphorylation. Free PKA catalytic subunits transfer the γ-phosphate of ATP onto serine or threonine residues within the consensus motif Arg-Arg-X-Ser/Thr-hydrophobic (R-R-X-S/T-Φ) on target proteins. Depending on cell type, targets include:
| Target | Effect of phosphorylation |
|---|---|
| Glycogen phosphorylase kinase | Activated → activates glycogen phosphorylase → glycogen breakdown |
| Glycogen synthase | Inhibited → glycogen synthesis halted |
| Hormone-sensitive lipase | Activated → triglyceride breakdown, fatty acid release |
| CFTR chloride channel | Activated → chloride/water secretion (target of cholera toxin) |
| CREB (cAMP response element-binding protein) | Activated → binds CRE DNA elements → transcription of target genes |
| L-type Ca²⁺ channels (cardiac muscle) | Activated → increased Ca²⁺ influx → stronger heart contraction |
Step 6 — Amplification, compartmentalization, and termination. Each step multiplies signal: one hormone-bound receptor can activate ~10–20 G proteins before it dissociates from ligand; each activated AC molecule can synthesize hundreds of cAMP molecules per second; each PKA catalytic subunit phosphorylates many substrate molecules processively. This tiered amplification — foreshadowing the broader idea of Signal Amplification and the Cascade Concept — converts a picomolar extracellular signal into a robust intracellular response. Signal termination requires several coordinated events, previewing Signal Termination and Desensitization: cAMP is hydrolyzed to 5′-AMP by cyclic nucleotide phosphodiesterases (PDEs), Gαs hydrolyzes its own bound GTP to GDP (intrinsic GTPase activity, accelerated by RGS proteins) and reassociates with Gβγ, and the receptor itself is desensitized by GPCR kinases and arrestins. A-kinase anchoring proteins (AKAPs) tether PKA holoenzymes near specific substrates and near PDEs, creating localized "signaling microdomains" so that a cAMP pulse near a mitochondrion or the nucleus doesn't indiscriminately activate every PKA molecule in the cell.
The evidence
The cAMP pathway is one of the best experimentally documented signaling systems in cell biology, largely because Earl W. Sutherland Jr. and colleagues built it up reaction-by-reaction using classic cell-free biochemistry between the 1950s and 1960s.
The central puzzle Sutherland addressed: glucagon and adrenaline, added to intact liver slices or perfused livers, caused glycogen breakdown (activation of glycogen phosphorylase) very rapidly. But how did a hormone acting at the cell surface activate an enzyme (phosphorylase) known to reside in the cytoplasm? Sutherland's group broke the liver cell open to trace the chain of causation biochemically.
Experiment 1 — Cell-free reconstitution demonstrates two separable steps. Sutherland and Theodore Rall (late 1950s) homogenized liver cells and separated the particulate fraction (containing plasma membranes) from the soluble (cytosolic) fraction (containing phosphorylase). They found:
- Adding glucagon or adrenaline to the particulate membrane fraction alone, in the presence of ATP and Mg²⁺, generated a heat-stable, dialyzable substance.
- This substance, when added to the soluble fraction (even without any hormone present), activated phosphorylase.
This was the critical proof of an intermediate: hormone action on the membrane fraction produced a diffusible chemical that, by itself, could activate the cytoplasmic enzyme system — hormone did not need to act directly on phosphorylase, and indeed could not, since hormone added to soluble fraction alone did nothing.
Experiment 2 — Isolation and chemical identification of the intermediate. Rall and Sutherland purified the heat-stable factor and identified it chemically as adenosine 3′,5′-cyclic monophosphate (cyclic AMP) — a cyclized nucleotide distinct from the linear nucleotides (AMP, ADP, ATP) already known. They showed synthetic cAMP, added directly to liver homogenates without any hormone, activated phosphorylase just as effectively as hormone-treated membrane extract, proving cAMP was sufficient, not merely correlated.
Experiment 3 — Identifying the enzyme that makes and destroys cAMP. The group demonstrated that the particulate (membrane) fraction contained an enzyme — adenylyl cyclase — that converts ATP to cAMP, and that this enzyme's activity increased when hormone was present, directly linking hormone binding at the membrane to cAMP production. They further identified phosphodiesterase as the enzyme hydrolyzing cAMP to 5′-AMP, explaining how the signal is turned off, and showed that methylxanthines (caffeine, theophylline) inhibit phosphodiesterase, prolonging cAMP's action — the biochemical basis for caffeine's stimulant effects on cellular signaling.
Experiment 4 — Generality across hormones and tissues. Sutherland and colleagues then showed that many different hormones (glucagon, adrenaline, ACTH, TSH, vasopressin), acting on many different tissues (liver, fat, adrenal cortex, thyroid, kidney), all raised intracellular cAMP levels prior to producing their characteristic physiological effect — but with tissue-specific downstream consequences. This established cAMP as a general "second messenger" concept: the first messenger (hormone) never enters the cell, and different first messengers can converge on the same second messenger, with target-cell identity (which genes and proteins the cell expresses) determining the specific downstream effect, not the identity of the hormone itself.
Why this mattered conceptually. Before Sutherland, it was unclear how a surface-binding event could be causally connected to intracellular enzyme activity — some biologists imagined direct hormone entry or vague "activation fields." Sutherland's cell-free, biochemically reconstituted, reductionist approach (breaking the cell into fractions, replacing hormone with its purified downstream product, and showing sufficiency) rigorously demonstrated a chemical relay, not a mysterious action-at-a-distance. Sutherland was awarded the 1971 Nobel Prize in Physiology or Medicine for discovering cAMP and establishing the second-messenger principle, a framework since extended to Ca²⁺, IP₃, diacylglycerol, and cyclic GMP.
Later corroborating evidence (structural and genetic). Alfred Gilman and Martin Rodbell (Nobel Prize, 1994) later identified the G proteins that couple receptor to adenylyl cyclase, explaining the missing link between hormone-receptor binding and cyclase activation (Sutherland's work predated knowledge of G proteins; his model initially had receptor directly activating cyclase). Cholera toxin studies (Gill and colleagues) showed that ADP-ribosylation of Gαs by the toxin locks it in the GTP-bound "on" state, causing unregulated, massive cAMP production in intestinal epithelial cells — a natural experiment (a bacterial toxin) that independently confirmed the Gαs → adenylyl cyclase → cAMP causal chain by showing that constitutively active Gαs alone is sufficient to permanently activate the pathway, producing cholera's severe watery diarrhea.
Worked examples
Example 1 — Quantifying amplification through the cascade. Suppose one molecule of adrenaline binds one β-adrenergic receptor on a liver cell. Assume the following (illustrative, biologically realistic) turnover numbers:
- Each activated receptor activates 20 Gαs molecules before ligand dissociates.
- Each Gαs-GTP activates one adenylyl cyclase molecule, and each active AC molecule synthesizes 100 cAMP molecules per second, and remains active for 10 seconds (so 1,000 cAMP molecules per AC).
- Each PKA holoenzyme requires 4 cAMP molecules to release 2 active catalytic subunits.
- Each active catalytic subunit phosphorylates 10 substrate molecules per second, remaining active for 10 seconds (100 phosphorylations per C subunit).
Calculation: 1. 1 receptor → 20 Gαs-GTP → 20 active AC molecules. 2. 20 AC × 1,000 cAMP each = 20,000 cAMP molecules. 3. 20,000 cAMP ÷ 4 cAMP per holoenzyme = 5,000 PKA holoenzymes activated → 10,000 active C subunits (2 per holoenzyme). 4. 10,000 C subunits × 100 phosphorylations each = 1,000,000 phosphorylation events from a single bound hormone molecule. This million-fold amplification (six orders of magnitude) is why hormone concentrations in the picomolar-to-nanomolar range in blood plasma can trigger large, whole-tissue metabolic shifts (e.g., a near-instant rise in blood glucose during a stress response). This calculation also illustrates why the pathway is described using Signal Amplification and the Cascade Concept: amplification is multiplicative at each enzymatic tier, not additive.
Example 2 — Reasoning through a clinical scenario: cholera toxin and constitutive cAMP. A patient presents with profuse, watery diarrhea after ingesting contaminated water; stool output can exceed 1 liter per hour in severe cases. Cholera toxin (from Vibrio cholerae) enters intestinal epithelial cells and ADP-ribosylates a specific arginine residue on Gαs, which:
- Blocks the intrinsic GTPase activity of Gαs (it can bind GTP normally but cannot hydrolyze it back to GDP).
- Locks Gαs permanently in its active, GTP-bound conformation, regardless of whether any hormone or receptor signal is present.
Reasoning through the consequence: with Gαs permanently "on," adenylyl cyclase is constitutively activated, driving cAMP to pathologically high, sustained levels — unlike normal transient pulses that are terminated within seconds by GTP hydrolysis. Chronically elevated PKA activity phosphorylates and activates the CFTR chloride channel in intestinal epithelial cells continuously, driving massive, unregulated Cl⁻ secretion into the gut lumen. Water follows osmotically, producing the profuse watery diarrhea characteristic of cholera. This scenario demonstrates, by a "natural experiment" in reverse, that Gαs-GTP is sufficient on its own to drive the entire downstream cascade — no hormone or receptor occupancy is required once Gαs is locked active — directly corroborating the causal chain Sutherland, Rodbell, and Gilman established biochemically. It also explains why oral rehydration therapy (replacing water and electrolytes) rather than blocking the pathway pharmacologically is the mainstay of cholera treatment, since the defect (constitutively active Gαs) is not reversible by a receptor antagonist.
Common misconceptions & traps
| Misconception | Correction |
|---|---|
| "Hormones enter the cell to activate cAMP-linked pathways." | Peptide/amine hormones (glucagon, adrenaline) act entirely at the extracellular receptor surface; cAMP is generated intracellularly by adenylyl cyclase, and the hormone itself never crosses the membrane. |
| "cAMP directly phosphorylates target proteins." | cAMP itself has no kinase activity; it is an allosteric activator that binds PKA's regulatory subunits, releasing the catalytic subunits, which do the actual phosphorylating. |
| "More cAMP always means a bigger, generic cellular response." | The response is tissue-specific — the same cAMP rise activates PKA in liver (glycogen breakdown) or in adrenal cortex (steroidogenesis) or in kidney (water reabsorption) depending on which PKA substrates and downstream genes that particular cell type expresses. |
| "Once cAMP is made, the signal persists until removed by an external stimulus." | cAMP is constantly and rapidly degraded by phosphodiesterase; its steady-state level reflects an ongoing balance of synthesis and degradation, giving fast, reversible kinetics even while the hormone is still bound. |
| "PKA is a cAMP-independent generic kinase, distinguishable only by name." | PKA (protein kinase A) is defined specifically as the kinase whose activity is switched by cAMP binding to its regulatory subunits; this dependency is the entire basis for calling it "cAMP-dependent protein kinase." |
The scientist behind it
Origins · 1 minEarl W. Sutherland Jr. and how this was discovered
Sutherland trained as a physician but redirected his career toward basic biochemical mechanism, working first with Carl and Gerty Cori (of glycogen metabolism fame) before establishing his own laboratory. Rather than studying whole animals or intact cells, he deliberately broke liver tissue into subcellular fractions — a reductionist strategy that let him ask precisely which piece of the cell responded to hormone, and which chemical intermediate carried that response onward. This approach — reconstructing a physiological effect from purified fractions and pure chemicals — was somewhat unfashionable in an era when many physiologists still favored studying intact, integrated systems, but it allowed him to nail down causation in a way whole-tissue experiments could not. He spent nearly two decades meticulously isolating, purifying, and chemically characterizing cyclic AMP and the enzymes that make and destroy it, culminating in a body of work recognized as one of the foundational discoveries of modern molecular endocrinology.
Where this matters today
Cardiology and pharmacology. β-adrenergic receptor agonists (e.g., dobutamine) raise cAMP and PKA activity in cardiac muscle, increasing contractility (positive inotropy) for acute heart failure management; β-blockers work by preventing adrenaline from initiating this same cascade, reducing heart rate and workload in hypertension and arrhythmia.
Respiratory medicine. Phosphodiesterase-4 (PDE4) inhibitors (e.g., roflumilast) and methylxanthines (theophylline) prolong cAMP signaling in airway smooth muscle and immune cells, used in chronic obstructive pulmonary disease (COPD) and asthma to promote bronchodilation and reduce inflammation.
Endocrinology and oncology. Activating mutations in the GNAS gene (encoding Gαs) that mimic cholera toxin's effect — locking Gαs in a GTP-bound state — cause McCune-Albright syndrome and are found in certain pituitary and thyroid tumors, driving constitutive hormone-independent cAMP production and unregulated cell proliferation or hormone secretion.
Infectious disease. Cholera toxin's ADP-ribosylation of Gαs is the direct mechanistic basis of cholera pathology, and oral rehydration solutions remain the frontline treatment worldwide, saving millions of lives, particularly in regions with limited healthcare infrastructure.
Neuroscience. cAMP/PKA/CREB signaling in hippocampal neurons is central to long-term potentiation and long-term memory consolidation, a key model system in studies of learning (notably in Eric Kandel's work on Aplysia sensitization, which extended Sutherland's biochemical logic into neural plasticity).
Reproductive and metabolic biology. Luteinizing hormone and follicle-stimulating hormone signal through Gs/cAMP/PKA in the ovary and testis to regulate steroidogenesis, relevant to fertility treatments; glucagon and epinephrine signaling through this pathway remain central to understanding diabetes and metabolic syndrome, and adenylyl cyclase/PDE modulators are active targets in current metabolic drug development.
Ask the tutor: How does the same cAMP/PKA signal produce opposite metabolic effects (glycogen breakdown vs. glycogen synthesis) within the very same liver cell?
Why is cAMP called a "second messenger" rather than just another signaling molecule?
The term distinguishes cAMP's role from the hormone itself. The hormone (e.g., glucagon) is the "first messenger" — it carries information from one cell (or gland) to another but never enters the target cell. cAMP is generated inside the target cell only after the hormone binds its surface receptor, and it is cAMP, not the hormone, that physically reaches and activates intracellular enzymes like PKA. The concept, established by Sutherland, generalizes: many different first messengers (hormones, neurotransmitters) can converge on the same second messenger system, and a cell's specific response depends on which second-messenger-responsive proteins that particular cell expresses, not on the chemical identity of the first messenger.
Why does the same cAMP signal produce different effects in liver versus adrenal cortex cells?
The specificity comes from which PKA substrates and target genes each cell type expresses, not from cAMP or PKA themselves, which are essentially identical across cell types. Liver cells express glycogen phosphorylase kinase and glycogen synthase as major PKA substrates, so a cAMP rise there triggers glycogen breakdown. Adrenal cortex cells instead express steroidogenic enzymes as PKA targets, so the same signal there triggers cortisol synthesis. This is a general principle in signal transduction: a shared intracellular signal (cAMP, Ca²⁺, or any second messenger) is interpreted differently depending on the cell's pre-existing protein repertoire, sometimes called "cell context."
How does caffeine relate to the cAMP pathway?
Caffeine and related methylxanthines (theophylline, theobromine) inhibit cyclic nucleotide phosphodiesterase, the enzyme that normally degrades cAMP to inactive 5′-AMP. By blocking degradation, caffeine causes cAMP to accumulate to higher levels and persist longer than it would after a normal, transient signaling event. This prolongs PKA activation in cells throughout the body, contributing to caffeine's stimulant and lipolytic effects, though caffeine also independently antagonizes adenosine receptors in the brain, a separate mechanism contributing to its alertness-promoting action.
Is adenylyl cyclase always activated by G proteins, or can it be inhibited too?
Both. There exist two classes of heterotrimeric G proteins acting on adenylyl cyclase with opposite effects: Gs (stimulatory), activated by receptors like the β-adrenergic and glucagon receptors, increases cAMP production, while Gi (inhibitory), activated by receptors like the α2-adrenergic and M2-muscarinic receptors, decreases cAMP production by inhibiting adenylyl cyclase. This dual control allows a single cell (e.g., a cardiac pacemaker cell) to have its cAMP level — and therefore heart rate — pushed up by sympathetic (adrenaline, Gs) input and pulled down by parasympathetic (acetylcholine, Gi) input, giving fine, bidirectional physiological control rather than a simple on/off switch.
What happens if adenylyl cyclase or PKA is mutated to be constitutively active, independent of hormone?
Constitutive activation removes the requirement for external hormonal signal entirely, producing continuous, unregulated downstream effects as if the hormone were always present. This is precisely the mechanism of cholera toxin (via Gαs) and of activating GNAS mutations found in some endocrine tumors and in McCune-Albright syndrome, where cells autonomously overproduce hormones (like cortisol or growth hormone) or, in cholera, chronically hypersecrete chloride and water. Such mutations illustrate that the pathway's regulatory "off-switches" (GTP hydrolysis, phosphodiesterase activity, receptor desensitization) are just as physiologically essential as the "on-switches," since losing them causes disease even without any change in receptor or hormone.
How does the cAMP pathway relate to G-protein signaling covered earlier, and what comes after it?
This pathway is a direct continuation of Heterotrimeric G Proteins as Molecular Switches: the GTP/GDP cycling of Gαs described there is exactly the switch that turns adenylyl cyclase on and off here. What this article adds is everything downstream of the G protein — cAMP synthesis, PKA activation, and phosphorylation of real physiological targets. The concepts of enzymatic amplification introduced here (one receptor → millions of phosphorylation events) generalize into the broader framework of Signal Amplification and the Cascade Concept, while the termination mechanisms (GTP hydrolysis, phosphodiesterase, receptor desensitization) are elaborated more fully under Signal Termination and Desensitization.
Does cAMP only activate PKA, or does it have other direct targets?
While PKA is the classic and best-characterized cAMP effector in this pathway, cAMP also directly binds and gates certain ion channels (cyclic-nucleotide-gated channels important in olfactory and photoreceptor neurons) and activates Epac (exchange protein directly activated by cAMP), a guanine-nucleotide exchange factor for the small GTPase Rap1, independent of PKA. These PKA-independent branches matter in specific contexts like insulin secretion and cell adhesion, but the PKA branch described in this article remains the dominant and most broadly conserved route through which cAMP controls metabolism, gene expression, and cardiac and smooth muscle physiology.